EAM
RARE icon

Exome Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Exome Asset Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-17,800
Closed -$831K – 67
2024
Q1 		$831K Buy
+17,800
New +$840K 0.71% 48

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Exome Asset Management's RARE Position: Q2 2024 in Review

Exome Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2024, closing a stake of 17,800 shares — an estimated $831K sold.

Exome Asset Management first reported a position in RARE in Q1 2024 and held it in 1 quarter. The position peaked at $831K in Q1 2024. 274 funds tracked by Wall St. Rank hold RARE as of Q2 2024.

  • Exome Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2024 after selling out during the quarter.
  • Exome Asset Management sold 17,800 Ultragenyx Pharmaceutical shares in Q2 2024, an estimated $831K.
  • Exome Asset Management first reported a position in Ultragenyx Pharmaceutical in Q1 2024 and held it in 1 quarter.
  • Exome Asset Management's Ultragenyx Pharmaceutical position peaked at $831K in Q1 2024.
  • 274 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2024.

Based on Exome Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.